These findings were supported by studies in mice expressing human NOX5 in a podocyte‐specific manner that exhibited podocyte dysfunction, albuminuria and hypertension, processes that were exacerbated when mice were made diabetic by treatment with streptozotocin (Jha et al., 2017). This evidence concerns the gene NOX5 and hypertensive disorder.